[1]
|
Strotmeyer, E.S. and Cauley, J.A. (2007) Diabetes mellitus, bone mineral density, and fracture risk. Current Opinion in Endocrinology, Diabetes and Obesity, 14, 429-435.
doi:10.1097/MED.0b013e3282f1cba3
|
[2]
|
Janghorbani, M., et al. (2006) Prospective study of diabetes and risk of hip fracture: The nurses’ health study. Diabetes Care, 29, 1573-1578. doi:10.2337/dc06-0440
|
[3]
|
Strotmeyer, E.S., et al. (2005) Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: The health, aging, and body composition study. Archives of Internal Medicine, 165, 1612-1617. doi:10.1001/archinte.165.14.1612
|
[4]
|
Cauley, J.A., et al. (2005) Bone mineral density and the risk of incident nonspinal fractures in black and white women. The Journal of the American Medical Association, 293, 2102-2108. doi:10.1001/jama.293.17.2102
|
[5]
|
Schwartz, A.V. and Sellmeyer, D.E. (2004) Women, type 2 diabetes, and fracture risk. Current Diabetes Reports, 4, 364-369. doi:10.1007/s11892-004-0039-z
|
[6]
|
Nicodemus, K.K. and Folsom, A.R. (2001) Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care, 24, 1192-1197.
doi:10.2337/diacare.24.7.1192
|
[7]
|
Wallace, C., et al. (2002) Incidence of falls, risk factors for falls, and fall-related fractures in individuals with diabetes and a prior foot ulcer. Diabetes Care, 25, 1983-1986.
doi:10.2337/diacare.25.11.1983
|
[8]
|
Schwartz, A.V., et al. (2002) Older women with diabetes have a higher risk of falls: A prospective study. Diabetes Care, 25, 1749-1754. doi:10.2337/diacare.25.10.1749
|
[9]
|
Keene, G.S., Parker, M.J. and Pryor, G.A. (1993) Mortality and morbidity after hip fractures. British Medical Journal, 307, 1248-1250. doi:10.1136/bmj.307.6914.1248
|
[10]
|
Haentjens, P., et al. (2001) The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. The Journal of Bone and Joint Surgery (American Volume), 83-A, 493-500.
|
[11]
|
Hollingworth, W., et al. (1993) Cost analysis of early discharge after hip fracture. British Medical Journal, 307, 903-906. doi:10.1136/bmj.307.6909.903
|
[12]
|
Botushanov, N.P. and Orbetzova, M.M. (2009) Bone mineral density and fracture risk in patients with type 1 and type 2 diabetes mellitus. Folia Medica (Plovdiv), 51, 12-17.
|
[13]
|
Kahn, S.E., et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. The New England Journal of Medicine, 355, 2427-2443.
doi:10.1056/NEJMoa066224
|
[14]
|
Douglas, I.J., et al. (2009) The risk of fractures associated with thiazolidinediones: A self-controlled case-series study. PLoS Medicine, 6, e1000154.
doi:10.1371/journal.pmed.1000154
|
[15]
|
Jones, S.G., et al. (2009) Distal upper and lower limb fractures associated with thiazolidinedione use. American Journal of Managed Care, 15, 491-496.
|
[16]
|
Dormuth, C.R., et al. (2009) Thiazolidinediones and fractures in men and women. Archives of Internal Medicine, 169, 1395-1402.
doi:10.1001/archinternmed.2009.214
|
[17]
|
Bodmer, M., et al. (2009) Risk of fractures with glitazones: A critical review of the evidence to date. Drug Safety, 32, 539-547.
doi:10.2165/00002018-200932070-00001
|
[18]
|
Bilik, D., et al. (2010) Thiazolidinediones and fractures: Evidence from translating research into action for diabetes. The Journal of Clinical Endocrinology & Metabolism, 95, 4560-4565.
|
[19]
|
Glintborg, D., et al. (2008) Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: A randomized, placebo-controlled trial. The Journal of Clinical Endocrinology & Metabolism, 93, 1696-1701.
doi:10.1210/jc.2007-2249
|
[20]
|
Yaturu, S., Bryant, B. and Jain, S.K. (2007) Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care, 30, 1574-1576.
doi:10.2337/dc06-2606
|
[21]
|
Ton, F.N., et al. (2005) Effects of low-dose prednisone on bone metabolism. Journal of Bone and Mineral Research, 20, 464-470. doi:10.1359/JBMR.041125
|
[22]
|
Vestergaard, P., Rejnmark, L. and Mosekilde, L. (2010) Are antiresorptive drugs effective against fractures in patients with diabetes? Calcified Tissue International, 88, 209-214.
|
[23]
|
Dagdelen, S., Sener, D. and Bayraktar, M. (2007) Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Advances in Therapy, 24, 1314-1320.
doi:10.1007/BF02877778
|
[24]
|
Lo, J.C., et al. (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporosis International, 17, 922-928.
doi:10.1007/s00198-006-0085-2
|
[25]
|
Cramer, J.A., et al. (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Current Medical Research & Opinion, 21, 1453-1460.
doi:10.1185/030079905X61875
|
[26]
|
Siris, E.S., et al. (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings, 81, 1013-1022.
doi:10.4065/81.8.1013
|
[27]
|
Huybrechts, K.F., Ishak, K.J. and Caro, J.J. (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone, 38, 922-928. doi:10.1016/j.bone.2005.10.022
|
[28]
|
Khamaisi, M., et al. (2007) Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. The Journal of Clinical Endocrinology & Metabolism, 92, 1172-1175. doi:10.1210/jc.2006-2036
|
[29]
|
Pitocco, D., et al. (2005) Six-month treatment with alendronate in acute Charcot neuroarthropathy: A randomized controlled trial. Diabetes Care, 28, 1214-1245.
doi:10.2337/diacare.28.5.1214
|
[30]
|
Ikeda, T., Manabe, H. and Iwata, K. (2004) Clinical significance of alendronate in postmenopausal type 2 diabetes mellitus. Diabetes & Metabolism, 30, 355-358.
doi:10.1016/S1262-3636(07)70128-3
|